All Programs
Popular
Urs Weber, MD
Urs Weber, MD
Steve Jackson, PharmD
Nisha Joseph, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODEMinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Irene Su, MD, MSCE
Aditya Bardia, MD, MPH, FASCO
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Roberto Leon-Ferre, MD
